Pure Global: Europe's AI MedTech Double Jeopardy Problem.

This week, we dissect the critical challenge facing AI MedTech innovators in the European Union. The convergence of the stringent Medical Device Regulation (MDR) and the new, formidable EU AI Act has created a complex web of overlapping requirements, potentially slowing innovation and creating massive compliance burdens. We explore how companies developing Software as a Medical Device (SaMD) must now navigate two separate, high-stakes regulatory pathways for a single product. This episode breaks down the specific points of friction, from redundant audits to conflicting definitions of what constitutes a 'significant change' to an algorithm. **Case Study:** A German startup with a breakthrough AI for melanoma detection has full MDR technical documentation ready. Now, they've been classified as a 'high-risk' system under the AI Act. They face the daunting prospect of a second, parallel conformity assessment, with new rules on data bias and algorithmic transparency. How can they avoid costly delays and de-risk their EU market launch? **This episode's key takeaways:** * What are the main areas where MDR and the EU AI Act overlap for AI medical devices? * How can a 'significant change' to your software be defined differently by each regulation? * What new data governance evidence is required by the AI Act that goes beyond MDR requirements? * Will Notified Bodies and AI Act authorities conduct separate audits on your Quality Management System? * Is it possible to build a single technical file that satisfies both regulatory bodies? * How should post-market surveillance be structured to monitor both device safety and algorithm performance? * What is the biggest mistake companies are making in their updated EU regulatory strategy? For more information, contact us at [email protected] or visit https://pureglobal.com/. For FREE AI tools and a free medical device database, visit https://pureglobal.ai/.